Hallmarks of Bone Metastasis

Johnson, Rachelle W.; Suva, Larry J.

doi:10.1007/s00223-017-0362-4

Cited by 44 publications

(39 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1,6,[11][12][13] The picture emerging from these studies highlights the fact that bone colonization by malig- Figure 1). 1,[13][14][15] In particular, the bone marrow microenvironment appears to play a pivotal role in facilitating certain key steps in this process, including seeding, survival, dormancy and resistance of cancer cells to clinical treatment. [14][15][16] The complex interplay involving tumour cells, bone microenvironment and bone-resident cells, may, in part, explain the difficulty in identifying effective therapeutic approaches for preventing skeletal metastases or achieving a complete eradication of metastatic foci.…”

Section: Introductionmentioning

confidence: 99%

“…1,[13][14][15] In particular, the bone marrow microenvironment appears to play a pivotal role in facilitating certain key steps in this process, including seeding, survival, dormancy and resistance of cancer cells to clinical treatment. [14][15][16] The complex interplay involving tumour cells, bone microenvironment and bone-resident cells, may, in part, explain the difficulty in identifying effective therapeutic approaches for preventing skeletal metastases or achieving a complete eradication of metastatic foci. 1,11,13 These observations suggest that effective treatment options to eradicate bone metastasis should rely on the combination of bonetargeted agents in association with different local and/or systemic antitumour treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Current status and future directions in the treatment of bone metastases from breast cancer

Leto

2019

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Breast cancer (BCa) is a malignant disease which preferentially metastasizes to the bone. 1,2 The consequences of this complication, which occurs in ~70% of metastatic BCa patients, may result in skeletal-related events (SREs) which encompass debilitating pain, impaired mobility, hypercalcaemia, pathologic fractures, spinal cord or nerve root compression, and bone marrow infiltration. 2,3 These pathological conditions negatively affect the performance status, quality of life (QoL) and survival of these patients. 3,4 The clinical treatment of bone metastasis from breast cancer is essentially aimed at palliating pain, maintaining function and preventing SREs. 3,4 This treatment requires a multidisciplinary approach, which is costly to the health care system. 4,5 On the other hand, although the current therapeutic options, based on the systemic administration of antiresorptive agents, 6 radiopharmaceuticals 7 or local treatment such as radiation therapy, 8 radiofrequency ablation 9 or surgery, 10 are effective in decreasing the tumour burden and slowing bone metastasis by reducing the extent of bone destruction, they are

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Current status and future directions in the treatment of bone metastases from breast cancer

Leto

2019

Clin Exp Pharma Physio

View full text Add to dashboard Cite

show abstract

“…Bone metastases are a major cause of morbidity and mortality in cancer patients [1][2][3]. Seventy to eighty percent of advanced breast and prostate cancer patients develop bone metastases, and metastases are also very common in lung, kidney, and thyroid cancers and in melanoma [2, 3•, 4].…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, signals from the primary tumor recruit monocytes, mesenchymal stem cells, and immature myeloid cells from the bone marrow to the primary tumor, where they are educated to become tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), and myeloid-derived suppressor cells (MDSCs), supporting the metastatic process [10••, 11]. The following steps have been thoroughly described by Johnson and Suva in their review BHallmarks of bone metastasis^ [1]. These hallmarks are extravasation, disruption of bone homeostasis, secretion of osteolytic growth factors, engagement in bone niche, interactions with the bone marrow microenvironment of the host, and responses to the physical environment, which are all needed in order to develop clinically detectable bone metastases [1].…”

Section: Introductionmentioning

confidence: 99%

Novel and Conventional Preclinical Models to Investigate Bone Metastasis

et al. 2019

View full text Add to dashboard Cite

Purpose of Review The purpose of this review is to emphasize the use of bone metastasis models in preclinical research. As classical models have been thoroughly discussed in recent reviews, we here highlight the most important aspects from these papers with a special focus on novel models developed during the past 5 years. Recent Findings Preclinical mouse models to study bone metastasis can be divided by cancer cell inoculation techniques (spontaneous, systemic, or local) or by immunological background of the mice (immunodeficient, syngeneic, or humanized). Additionally, novel computational, in vitro co-culture, and humanized bone models have been established. Summary Various models can be used to approach distinct research questions. Understanding limitations of the models is essential when planning a study and interpreting the results. Development of novel models will increase understanding of the complex biology and advance the discovery of new therapies targeting bone metastases.

show abstract

“…And thus, the next two articles provide an extensive review of the hallmarks of secondary breast [2] and prostate [3] in bone, and highlight current and future treatments for patients with CIBD caused by these cancers.…”

mentioning

confidence: 99%

Recent Trends and Advances in Cancer-Induced Bone Disease

Idris

2018

Calcif Tissue Int

View full text Add to dashboard Cite

In recent years, cancer-induced bone disease (CIBD) has become an important area of research to many, and scientific research in this area has been growing within the bone research community. The source of this enthusiasm was the expectation that incidences of skeletal related events in cancer patients would increase, as cancer becomes a chronic disease. Furthermore, drug treatments that are available in clinical practice for advanced cancer patients are effective at slowing disease progression and its recurrence; however, bone metastasis, spread of primary bone cancer to distant organs and bone pain still remain serious clinical problems, and are often inadequately managed in patients.In this special "cancer and bone" issue of Calcified Tissue International and Musculoskeletal Research journal, I assembled a collection of review articles that focus on "hot topics" in the field of CIBD. The reviews are intended for basic and clinical bone scientists with special interest in skeletal disorders associated with primary bone cancers and bone metastasis. All reviews have been written by experts in the field and are well researched. The list of authors also includes a group of early-and mid-career researchers working on the field of CIBD research. This blend offers special support to up-coming investigators and future leaders.The special issue begins with a review article by Rucci and Teti that tackles the topic of "osteomimicry" and how this phenomenon influences the ability of metastatic cancer cells that originated in distant organs such as the breast and prostate to adapt to the skeleton, prosper and develop the ability to disrupt the function of native cells in the tumour microenvironment [1].Osteolytic bone metastases are a common cause of morbidity in patients with advanced breast and prostate. And thus, the next two articles provide an extensive review of the hallmarks of secondary breast [2] and prostate [3] in bone, and highlight current and future treatments for patients with CIBD caused by these cancers.The mechanisms by which tumour cells metastasize to bone have eluded bone researchers for centuries. Furthermore, many of the factors and signalling pathways that have been implicated in this process remain unknown or their action is poorly understood. In this issue, Rumney and colleagues provide an insight into the role of hypoxia in the regulation of bone metastasis and summarise the key tumour-and bone-derived factors implicated in hypoxiainduced CIBD [4].CIBD, bone pain and metastasis are serious complications in patients with primary bone tumours. To cover this topic, I included an article by Brown et al. that discusses the histological, molecular and genetic heterogeneity among bone sarcomas, with particular emphasis on osteosarcoma and Ewing sarcoma and chondrosarcoma [5]. The review also summarises the therapeutic advances in the field of primary bone cancer.Multiple myeloma (MM) is another aggressive form of cancer, and CIBD and bone pain caused by MM cells are serious consequences of the disease. ...

show abstract

Hallmarks of Bone Metastasis

Cited by 44 publications

References 113 publications

Current status and future directions in the treatment of bone metastases from breast cancer

Current status and future directions in the treatment of bone metastases from breast cancer

Novel and Conventional Preclinical Models to Investigate Bone Metastasis

Recent Trends and Advances in Cancer-Induced Bone Disease

Contact Info

Product

Resources

About